{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670321287956736.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.amjcard.2008.10.002"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0002914908017505?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0002914908017505?httpAccept=text/plain"}},{"identifier":{"@type":"PMID","@value":"19068318"}},{"identifier":{"@type":"HANDLE","@value":"11577/2437750"}}],"dc:title":[{"@value":"The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia"}],"description":[{"notation":[{"@value":"Despite achieving targets for low-density lipoprotein (LDL) cholesterol, blood pressure, and glycemia in accordance with current standards of care, patients with dyslipidemia remain at high residual risk of vascular events. Atherogenic dyslipidemia, characterized by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol, often with elevated apolipoprotein B and non-HDL cholesterol, is common in patients with established cardiovascular disease (CVD), type 2 diabetes mellitus, or metabolic syndrome and contributes to both macrovascular and microvascular residual risk. However, atherogenic dyslipidemia is largely underdiagnosed and undertreated in clinical practice. The Residual Risk Reduction Initiative (R3i) was established to address this highly relevant clinical issue. The aims of this position paper are (1) to highlight evidence that atherogenic dyslipidemia is associated with residual macrovascular and microvascular risk in patients at high risk for CVD, despite current standards of care for dyslipidemia and diabetes; and (2) to recommend therapeutic intervention for reducing this residual vascular risk supported by evidence and expert consensus. Lifestyle modification with nutrition and exercise is an important, effective, and underutilized first step in reducing residual vascular risk. Therapeutic intervention aimed at achievement of all lipid targets is also often required. Combination lipid-modifying therapy, with the addition of niacin, a fibrate, or omega-3 fatty acids to statin therapy, increases the probability of achieving all lipid goals. Outcomes studies are in progress to evaluate whether these combination treatment strategies translate to a clinical benefit greater than that achieved with statins alone. The R3i highlights the need to address with lifestyle and/or pharmacotherapy the high level of residual risk of CVD events and microvascular complications among patients with dyslipidemia receiving therapy for high levels of LDL cholesterol and for diabetes in accordance with current standards of care."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670321287956611","@type":"Researcher","foaf:name":[{"@value":"Jean-Charles Fruchart"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956738","@type":"Researcher","foaf:name":[{"@value":"Frank Sacks"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956609","@type":"Researcher","foaf:name":[{"@value":"Michel P. Hermans"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956615","@type":"Researcher","foaf:name":[{"@value":"Gerd Assmann"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956612","@type":"Researcher","foaf:name":[{"@value":"W. Virgil Brown"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956622","@type":"Researcher","foaf:name":[{"@value":"Richard Ceska"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956739","@type":"Researcher","foaf:name":[{"@value":"M. John Chapman"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956620","@type":"Researcher","foaf:name":[{"@value":"Paul M. Dodson"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956608","@type":"Researcher","foaf:name":[{"@value":"Paola Fioretto"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956614","@type":"Researcher","foaf:name":[{"@value":"Henry N. Ginsberg"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956737","@type":"Researcher","foaf:name":[{"@value":"Takashi Kadowaki"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956613","@type":"Researcher","foaf:name":[{"@value":"Jean-Marc Lablanche"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956621","@type":"Researcher","foaf:name":[{"@value":"Nikolaus Marx"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956617","@type":"Researcher","foaf:name":[{"@value":"Jorge Plutzky"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956736","@type":"Researcher","foaf:name":[{"@value":"Željko Reiner"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956740","@type":"Researcher","foaf:name":[{"@value":"Robert S. Rosenson"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956618","@type":"Researcher","foaf:name":[{"@value":"Bart Staels"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956619","@type":"Researcher","foaf:name":[{"@value":"Jane K. Stock"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956741","@type":"Researcher","foaf:name":[{"@value":"Rody Sy"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956742","@type":"Researcher","foaf:name":[{"@value":"Christoph Wanner"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956616","@type":"Researcher","foaf:name":[{"@value":"Alberto Zambon"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321287956610","@type":"Researcher","foaf:name":[{"@value":"Paul Zimmet"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00029149"}],"prism:publicationName":[{"@value":"The American Journal of Cardiology"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2008-11","prism:volume":"102","prism:number":"10","prism:startingPage":"1K","prism:endingPage":"34K"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0002914908017505?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0002914908017505?httpAccept=text/plain"}],"createdAt":"2008-11-12","modifiedAt":"2025-11-02","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Incidence","dc:title":"Incidence"},{"@id":"https://cir.nii.ac.jp/all?q=Global%20Health","dc:title":"Global Health"},{"@id":"https://cir.nii.ac.jp/all?q=Lipids","dc:title":"Lipids"},{"@id":"https://cir.nii.ac.jp/all?q=Risk%20Assessment","dc:title":"Risk Assessment"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Outcome","dc:title":"Treatment Outcome"},{"@id":"https://cir.nii.ac.jp/all?q=Risk%20Factors","dc:title":"Risk Factors"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Vascular%20Diseases","dc:title":"Vascular Diseases"},{"@id":"https://cir.nii.ac.jp/all?q=Dyslipidemias","dc:title":"Dyslipidemias"},{"@id":"https://cir.nii.ac.jp/all?q=Hypolipidemic%20Agents","dc:title":"Hypolipidemic Agents"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050845764129174272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential"},{"@value":"The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: a consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation."},{"@value":"The selective peroxisome proliferator-activated receptor α modulator (SPPARMα) paradigm: Conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002215981398400","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004236871861376","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"CRISPR/Cas9-mediated Angptl8 knockout suppresses plasma triglyceride concentrations and adiposity in rats"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013168769250944","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Atherogenic Dyslipidemia and Residual Vascular Risk After Stroke or Transient Ischemic Attack"}]},{"@id":"https://cir.nii.ac.jp/crid/1360287144459625600","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate"}]},{"@id":"https://cir.nii.ac.jp/crid/1390003825194766848","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679408425984","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Development of Antisense Drugs for Dyslipidemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680085650688","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Comparison of Effects of α-Glucosidase Inhibitors and Glinide Drugs on Endothelial Dysfunction in Diabetic Patients With Coronary Artery Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1390304704716207872","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Atherogenic Dyslipidemia Is Critically Related to Aortic Complicated Lesions in Cryptogenic Stroke"}]},{"@id":"https://cir.nii.ac.jp/crid/1390564238048574464","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Association of Serum Triglycerides With Arterial Stiffness in Subjects With Low Levels of Low-Density Lipoprotein Cholesterol"}]},{"@id":"https://cir.nii.ac.jp/crid/1390570707168337536","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Real-world Profile of a Selective Peroxisome Proliferator-activated Receptor α Modulator (SPPARMα) in Japanese Patients with Renal Impairment and Dyslipidemia"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.amjcard.2008.10.002"},{"@type":"OPENAIRE","@value":"doi_dedup___::eb45d74d5377862f3a06998ce306a95d"},{"@type":"CROSSREF","@value":"10.1194/jlr.m082099_references_DOI_T6ZanTT7Radh0EBxBnl1ZPoeYnl"},{"@type":"CROSSREF","@value":"10.5551/jat.50807_references_DOI_T6ZanTT7Radh0EBxBnl1ZPoeYnl"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.6871-20_references_DOI_T6ZanTT7Radh0EBxBnl1ZPoeYnl"},{"@type":"CROSSREF","@value":"10.1161/strokeaha.121.034593_references_DOI_T6ZanTT7Radh0EBxBnl1ZPoeYnl"},{"@type":"CROSSREF","@value":"10.5551/jat.rv16001_references_DOI_T6ZanTT7Radh0EBxBnl1ZPoeYnl"},{"@type":"CROSSREF","@value":"10.3390/ijms20225682_references_DOI_T6ZanTT7Radh0EBxBnl1ZPoeYnl"},{"@type":"CROSSREF","@value":"10.5551/jat.65289_references_DOI_T6ZanTT7Radh0EBxBnl1ZPoeYnl"},{"@type":"CROSSREF","@value":"10.1253/circj.cj-13-0918_references_DOI_T6ZanTT7Radh0EBxBnl1ZPoeYnl"},{"@type":"CROSSREF","@value":"10.1016/j.jacl.2017.10.006_references_DOI_T6ZanTT7Radh0EBxBnl1ZPoeYnl"},{"@type":"CROSSREF","@value":"10.1253/circj.cj-18-0607_references_DOI_T6ZanTT7Radh0EBxBnl1ZPoeYnl"},{"@type":"CROSSREF","@value":"10.1186/s12933-019-0864-7_references_DOI_T6ZanTT7Radh0EBxBnl1ZPoeYnl"}]}